Nucor earnings beat by $0.08, revenue fell short of estimates
Susan Bobulsky, the Chief Commercial Officer of Adaptive Biotechnologies Corp (NASDAQ:ADPT), a $1.15 billion market cap company whose stock has surged over 80% in the past six months, recently executed a significant stock transaction. On March 5, she sold 26,023 shares of the company’s common stock at an average price of $6.98 per share, totaling approximately $181,640. This sale was conducted to cover tax withholding obligations related to the vesting of restricted stock units (RSUs), as mandated by the company’s equity incentive plans.
Additionally, Bobulsky acquired 119,971 shares of common stock on March 4, at no cost, as part of her compensation package. On the same day, she also received stock options for 180,029 shares, which have an exercise price of $8.12 per share and will vest over four years starting from March 2026. According to InvestingPro analysis, ADPT maintains strong liquidity with a current ratio of 2.89, though analysts expect the company to remain unprofitable this year. For deeper insights into ADPT’s financial health and future prospects, explore the comprehensive Pro Research Report, available exclusively on InvestingPro.
Following these transactions, Bobulsky’s direct ownership in Adaptive Biotechnologies stands at 347,238 shares.
In other recent news, Adeptus Biotechnologies Corp. reported strong financial results for the fourth quarter, exceeding analyst expectations. The company posted Q4 revenue of $47.5 million, surpassing the consensus estimate of $46.15 million, marking a 4% year-over-year increase. The adjusted loss per share was $0.23, which was better than the anticipated $0.25 loss. Adeptus’s Minimal Residual Disease (MRD) business, contributing 85% of Q4 revenue, grew 31% year-over-year to $40.1 million, while Immune Medicine revenue saw a decline of 51% to $7.3 million. For 2025, the company projects MRD business revenue between $175 million and $185 million, with operating expenses estimated at $340-$350 million and a cash burn of $60-$70 million. Scotiabank (TSX:BNS) analyst Sung Ji Nam raised the price target for Adeptus Biotechnologies to $12.00 from $10.00, maintaining a Sector Outperform rating due to the company’s strong fiscal performance. The analyst highlighted the significant growth potential of the MRD business and the reduced risk profile of the Immune Medicine segment. Adeptus ended 2024 with $256 million in cash reserves, and the company aims for MRD adjusted EBITDA profitability in the second half of 2025.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.